VolitionRX Limited (VNRX)
VNRX trades on NYSE in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/93314/000147793226001832/0001477932-26-001832-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VNRX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | Singapore |
| IPO year | 2015 |
| SEC CIK | 0000093314 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.7M |
| Net income | -$23.4M |
| Operating income | -$21.7M |
| Net margin | -1352.2% |
| Operating margin | -1258.5% |
| Revenue growth | +40.0% |
| Cash | $1.1M |
| Total assets | $6.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing." | 10-Q 2026-11-12 |
| Cash and burn | $2.4M cash; operating cash flow -$5.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 36,082,903 (2026-11-05); 122,801,572 a year earlier; 78,685,873 three years earlier. 1y figure adjusted for split (1-for-20 overall); 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-04-28 | Source 2026-04-28 |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-09 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-04-23 |
| Auditor | Sadler, Gibb & Associates, LLC, Draper, Utah, United States | PCAOB Form AP 2026-04-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $137K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6M | -$3.8M | -$4.6M | $2.4M | $6.7M | $3.4M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $399K | -$7.3M | -$5.2M | $2.8M | $7.1M | $2.5M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $985K | -$6.7M | -$5.3M | $3.1M | $7.3M | $2.5M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $447K | -$6.3M | -$5.5M | $1.1M | $6.7M | $1.7M | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $627K | -$5.4M | -$3.6M | $200K | $6.5M | $1.5M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $407K | -$6.3M | -$6.3M | $2.3M | $6.8M | $1.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $246K | -$5.4M | -$4.3M | $2.6M | $6.4M | $1.3M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $192K | -$5.8M | -$5.4M | $3.3M | $4.8M | $1.2M | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-08-28 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-06-02 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +15.0% |
| 1 month | +27.8% |
| 3 months | -63.5% |
| Year to date | -95.6% |
| 1 year | -96.7% |
| From 52-week high | -96.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BMRA | Biomerica Inc. | $1.32 | -2.94% | $6.1M |
| CDIO | Cardio Diagnostics Holdings Inc. | $1.79 | -7.26% | $5.3M |
| TRIB | Trinity Biotech plc | $5.38 | -11.89% | $4.4M |
| QCLS | Q/C Technologies Inc. | $0.3210 | +4.80% | $2.6M |
| IMDX | Insight Molecular Diagnostics Inc. | $1.86 | -13.08% | $60.9M |
| VRAX | Virax Biolabs Group Limited | $0.4480 | -26.87% | $603K |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier